Different tissue responses for iodine and iodide in rat thyroid and mammary glands
- PMID: 7577324
- DOI: 10.1007/BF02788999
Different tissue responses for iodine and iodide in rat thyroid and mammary glands
Abstract
This research describes the effects of short-term elemental iodine (I2) and iodide (I-) replacement on thyroid glands and mammary glands of iodine-deficient (ID) Sprague-Dawley female rats. Iodine deficiency causes atypical tissue and physiologic changes in both glands. Tissue histopathology and the endocrine metabolic parameters, such as serum TT4, tissue and body weights, and vaginal smears, are compared. A moderate reduction in thyroid size from the ID control (IDC) was noted with both I- and I2, whereas serum total thyroxine approached the normal control with both I- and I2, but was lower in IDC. Thyroid gland IDC hyperplasia was reduced modestly with I2, but eliminated with I-. Lobular hyperplasia of the mammary glands decreased with I2 and increased with I- when compared with the IDC; extraductal secretions remained the same as IDC with I2, but increased with I-; and periductal fibrosis was markedly reduced with I2, but remained severe with I-. Thus, orally administered I2 or I- in trace doses with similar iodine availability caused different histopathological and endocrine patterns in thyroid and mammary glands of ID rats. The significance of this is that replacement therapy with various forms of iodine are tissue-specific.
Similar articles
-
Comparison of the effects of iodine and iodide on thyroid function in humans.J Toxicol Environ Health A. 1998 Sep 25;55(2):93-106. doi: 10.1080/009841098158539. J Toxicol Environ Health A. 1998. PMID: 9761130 Clinical Trial.
-
Inhibition of N-methyl-N-nitrosourea-induced mammary carcinogenesis by molecular iodine (I2) but not by iodide (I-) treatment Evidence that I2 prevents cancer promotion.Mol Cell Endocrinol. 2005 May 31;236(1-2):49-57. doi: 10.1016/j.mce.2005.03.001. Epub 2005 Apr 13. Mol Cell Endocrinol. 2005. PMID: 15922087
-
Uptake and gene expression with antitumoral doses of iodine in thyroid and mammary gland: evidence that chronic administration has no harmful effects.Thyroid. 2007 Sep;17(9):851-9. doi: 10.1089/thy.2007.0122. Thyroid. 2007. PMID: 17956159
-
Pathogenesis of hyperthyroidism. Dual role of iodine in thyroid function.Lancet. 1968 Mar 30;1(7544):671-2. doi: 10.1016/s0140-6736(68)92104-1. Lancet. 1968. PMID: 4170655 Review. No abstract available.
-
Iodine-induced thyroid inhibition and cell necrosis: two consequences of the same free-radical mediated mechanism?Mol Cell Endocrinol. 1996 Jul 23;121(1):101-3. doi: 10.1016/0303-7207(96)03848-8. Mol Cell Endocrinol. 1996. PMID: 8865171 Review. No abstract available.
Cited by
-
Iodine loaded nanoparticles with commercial applicability increase survival in mice cancer models with low degree of side effects.Cancer Rep (Hoboken). 2023 Aug;6(8):e1843. doi: 10.1002/cnr2.1843. Epub 2023 Jun 2. Cancer Rep (Hoboken). 2023. PMID: 37269144 Free PMC article.
-
Molecular Iodine Has Extrathyroidal Effects as an Antioxidant, Differentiator, and Immunomodulator.Int J Mol Sci. 2021 Jan 27;22(3):1228. doi: 10.3390/ijms22031228. Int J Mol Sci. 2021. PMID: 33513754 Free PMC article. Review.
-
The correlation between breast cancer and urinary iodine excretion levels.J Int Med Res. 2018 Feb;46(2):687-692. doi: 10.1177/0300060517717535. Epub 2017 Aug 31. J Int Med Res. 2018. PMID: 28856936 Free PMC article.
-
Antiproliferative/cytotoxic effects of molecular iodine, povidone-iodine and Lugol's solution in different human carcinoma cell lines.Oncol Lett. 2016 Sep;12(3):2159-2162. doi: 10.3892/ol.2016.4811. Epub 2016 Jul 5. Oncol Lett. 2016. PMID: 27602156 Free PMC article.
-
Activation of peroxisome proliferator-activated receptor gamma is crucial for antitumoral effects of 6-iodolactone.Mol Cancer. 2015 Sep 17;14:168. doi: 10.1186/s12943-015-0436-8. Mol Cancer. 2015. PMID: 26376791 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
